Oppenheimer Cuts Veeva Systems (NYSE:VEEV) Price Target to $275.00

27 Feb 2026, 07:08 by Kim Johansen · The Markets Daily

Veeva Systems (NYSE:VEEV – Free Report) had its price objective trimmed by Oppenheimer from $325.00 to $275.00 in a report issued on Tuesday,Benzinga reports. The firm currently has an outperform rating on the technology company’s stock.

Several other brokerages also recently issued reports on VEEV. The Goldman Sachs Group initiated coverage on Veeva Systems in a research note on Tuesday, January 13th. They issued a “sell” rating and a $215.00 price objective for the company. KeyCorp reiterated a “sector weight” rating on shares of Veeva Systems in a report on Friday, December 12th. BMO Capital Markets initiated coverage on shares of Veeva Systems in a report on Thursday, November 13th. They set a “market perform” rating and a $300.00 price target for the company. Truist Financial upgraded shares of Veeva Systems from a “hold” rating to a “buy” rating in a research note on Thursday, January 8th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $355.00 target price on shares of Veeva Systems in a research report on Friday, November 21st. Eighteen analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $293.71.

View Our Latest Report on VEEV

Veeva Systems Stock Performance

NYSE VEEV opened at $182.84 on Tuesday. The firm’s 50 day moving average price is $207.69 and its two-hundred day moving average price is $251.18. Veeva Systems has a twelve month low of $168.13 and a twelve month high of $310.50. The stock has a market cap of $30.06 billion, a price-to-earnings ratio of 35.57, a PEG ratio of 1.22 and a beta of 1.08.

Veeva Systems declared that its board has approved a stock buyback program on Monday, January 5th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the technology company to repurchase up to 5.5% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Insiders Place Their Bets

In other Veeva Systems news, insider Thomas D. Schwenger sold 1,000 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $231.43, for a total value of $231,430.00. Following the completion of the sale, the insider owned 23,204 shares of the company’s stock, valued at $5,370,101.72. The trade was a 4.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Veeva Systems

A number of large investors have recently added to or reduced their stakes in VEEV. GPS Wealth Strategies Group LLC lifted its stake in shares of Veeva Systems by 196.4% in the third quarter. GPS Wealth Strategies Group LLC now owns 83 shares of the technology company’s stock worth $25,000 after buying an additional 55 shares during the last quarter. Raiffeisen Bank International AG bought a new stake in Veeva Systems during the third quarter valued at about $28,000. OLD Second National Bank of Aurora acquired a new stake in shares of Veeva Systems in the third quarter valued at about $30,000. Legacy Investment Solutions LLC acquired a new stake in shares of Veeva Systems in the second quarter valued at about $32,000. Finally, Board of the Pension Protection Fund bought a new position in shares of Veeva Systems in the fourth quarter worth about $27,000. Institutional investors own 88.20% of the company’s stock.

More Veeva Systems News

Here are the key news stories impacting Veeva Systems this week:

Positive Sentiment: Company authorized a new ~US$2 billion share buyback and analysts have recently revised some estimates upward, supporting renewed investor focus on valuation and capital return. This buyback is being cited as a main catalyst for renewed demand. A Look At Veeva Systems (VEEV) Valuation
Positive Sentiment: Veeva launched “eSource” to streamline clinical-trial data capture — a product extension that can expand stickiness with life-sciences customers and support subscription revenue growth. Product launches that improve workflow integration are generally positive for recurring SaaS sales. Veeva Systems Inc. (VEEV) Launches eSource
Positive Sentiment: Market headlines and broad sector flows have highlighted Veeva as a top mover today, helping momentum-driven buying. General coverage pointing to the stock “skyrocketing” has likely amplified intraday demand. Veeva Systems, Upstart, Paycom, Commvault, and Agilysys shares skyrocket
Neutral Sentiment: Stifel trimmed its price target (from $320 to $212) but retained a Buy rating, signaling mixed analyst sentiment: lower upside expectations but continued buy-side endorsement. Stifel price target change
Neutral Sentiment: Coverage pieces (Zacks, recent market summaries) note Veeva as a trending name — raising attention but not changing fundamentals by itself. Veeva trending stock note
Negative Sentiment: Multiple broker price targets were lowered recently (Barclays, Oppenheimer among them), reflecting more cautious medium-term estimates even as most maintain constructive ratings — a headwind for valuation. Barclays price target note Oppenheimer lowers price target
Negative Sentiment: Short interest rose ~26% in February to roughly 6.33M shares (about 4.3% of float), increasing bearish pressure and potential volatility should sentiment change. (Data reported Feb 13.)

Veeva Systems Company Profile

(Get Free Report)

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.